List of adverse effects of aripiprazole

The rates of adverse effects of aripiprazole are:[1][2][3][4][5]

Adults edit

Very common (>10% incidence) edit

Common (1–10% incidence) edit

Uncommon (0.1–1% incidence) edit

Rare (<0.1%) edit

Sudden unexplained death has been reported, however the frequency is unknown.[13]


Common in children edit

  • Feeling sleepy
  • Headache
  • Vomiting
  • Fatigue
  • Increased appetite
  • Insomnia
  • Nausea
  • Stuffy nose
  • Weight gain
  • Uncontrolled movement such as restlessness, tremor muscle stiffness[7]

References edit

  1. ^ "Product Information for ABILIFY Aripiprazole Tablets & Orally Disintegrating Tablets". TGA eBusiness Services. Bristol-Myers Squibb Australia Pty Ltd. 1 November 2012. Retrieved 22 October 2013.
  2. ^ "ABILIFY (aripiprazole) tablet ABILIFY (aripiprazole) solution ABILIFY DISCMELT (aripiprazole) tablet, orally disintegrating ABILIFY (aripiprazole) injection, solution [Otsuka America Pharmaceutical, Inc.]". DailyMed. Otsuka America Pharmaceutical, Inc. April 2013. Retrieved 22 October 2013.
  3. ^ "Abilify Tablets, Orodispersible Tablets, Oral Solution - Summary of Product Characteristics (SPC)". electronic Medicines Compendium. Otsuka Pharmaceuticals (UK) Ltd. 20 September 2013. Archived from the original on 4 March 2016. Retrieved 22 October 2013.
  4. ^ "ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS" (PDF). European Medicines Agency. Otsuka Pharmaceutical Europe Ltd. Retrieved 22 October 2013.
  5. ^ "Abilify Discmelt, Abilify Maintena (aripiprazole) dosing, indications, interactions, adverse effects, and more". Medscape Reference. WebMD. Retrieved 22 October 2013.
  6. ^ a b Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, Samara M, Barbui C, Engel RR, Geddes JR, Kissling W, Stapf MP, Lässig B, Salanti G, Davis JM (September 2013). "Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis". Lancet. 382 (9896): 951–962. doi:10.1016/S0140-6736(13)60733-3. PMID 23810019. S2CID 32085212.
  7. ^ a b "ABILIFY (aripiprazole) [package insert]" (PDF). Otsuka Pharmaceutical Co, Ltd. Retrieved 18 October 2012.
  8. ^ Felin, Tricia; Naveed, Sadiq; Chaudhary, Amna M. (2018-05-01). "Aripiprazole-Induced Neutropenia: Case Report and Literature Review". Journal of Psychosocial Nursing and Mental Health Services. 56 (5). SLACK, Inc.: 21–24. doi:10.3928/02793695-20180419-02. ISSN 0279-3695. PMID 29715374.
  9. ^ Thabet, Farouq I.; Sweis, Rochelle T.; Joseph, Suja A. (2013). "Aripiprazole-Induced Seizure in a 3-Year-Old Child". Clinical Neuropharmacology. 36 (1). Ovid Technologies (Wolters Kluwer Health): 29–30. doi:10.1097/wnf.0b013e3182767efb. ISSN 0362-5664. PMID 23334073.
  10. ^ Abbasian C, Power P (March 2009). "A case of aripiprazole and tardive dyskinesia". J Psychopharmacol (Oxford). 23 (2): 214–5. doi:10.1177/0269881108089591. PMID 18515468. S2CID 206489666.
  11. ^ Zaidi SH, Faruqui RA (January 2008). "Aripiprazole is associated with early onset of Tardive Dyskinesia like presentation in a patient with ABI and psychosis". Brain Inj. 22 (1): 99–102. doi:10.1080/02699050701822493. PMID 18183513. S2CID 11197371.
  12. ^ Maytal G, Ostacher M, Stern TA (June 2006). "Aripiprazole-related tardive dyskinesia". CNS Spectr. 11 (6): 435–9. doi:10.1017/s1092852900014632. PMID 16816781. S2CID 41849016.
  13. ^ http://www.medicines.org.uk/EMC/pdfviewer.aspx?isAttachment=true&documentid=16161 [dead link]